Atossa Genetics is a healthcare company focused on the development of locally-administered pharmaceuticals for the treatment of pre-cancer and early stage breast cancer.
Atossa Genetics to Host 2015 Financial Results and Company Update Conference Call on Wednesday, March 30, 2016
Atossa Genetics Announces the Opening of Its First Phase 2 Clinical Trial of Intraductal Fulvestrant Administration in Women With Ductal Carcinoma in Situ (DCIS) or Breast Cancer
Atossa Genetics Completes Sale of Its Wholly-Owned Subsidiary, NRLBH
More Press Releases
Learn more about Atossa Genetics
Learn more about our programs
Contact Atossa Genetics today!